3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Burkitt Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Interventions
Rituximab
47
Cyclophosphamide
26
fludarabine
13
ibrutinib
12
Doxorubicin
11
Vincristine
10
Etoposide
10
Cytarabine
10
Prednisone
9
Bortezomib
9
pembrolizumab
7
fludarabine phosphate
6
Lenalidomide
6
Inotuzumab Ozogamicin
6
obinutuzumab
5
Mycophenolic Acid
5
Melphalan
5
Carmustine
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Tacrolimus
4
Prednisolone
4
Methotrexate
4
Gemcitabine
4
Bendamustine Hydrochloride
4
Antilymphocyte Serum
4
tocilizumab
3
tazemetostat
3
Whole-Body Irradiation
3
Vorinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell
×
tisagenlecleucel
×
Clear all
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts